A prospective study of serum lipids and risk of diabetic macular edema in type 1 diabetes

Diabetes

Volumn 53, Issue 11, 2004, Pages 2883-2892

  Miljanovic, Biljana ^a   Glynn, Robert J ^a,b   Nathan, David M ^c   Manson, JoAnn E ^a,b   Schaumberg, Debra A ^a,b,d  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; CHOLESTEROL; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL STUDY; CLINICAL TRIAL; DIABETES CONTROL AND COMPLICATIONS TRIAL; DIABETIC RETINOPATHY; FEMALE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; NONBIOLOGICAL MODEL; PREDICTION; PRIMARY PREVENTION; PRIORITY JOURNAL; RANDOMIZATION; RETINA EXUDATE; RETINA MACULA EDEMA; RISK FACTOR; VISUAL IMPAIRMENT;

ANALYSIS OF VARIANCE; BIOLOGICAL MARKERS; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DIABETES MELLITUS, TYPE 1; DIABETIC RETINOPATHY; HUMANS; LIPIDS; MACULAR DEGENERATION; MULTIVARIATE ANALYSIS; RETROSPECTIVE STUDIES; RISK FACTORS; TRIGLYCERIDES;

EID: 7044249532     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.53.11.2883     Document Type: Article

References (42)

1. Aiello LM: Perspectives on diabetic retinopathy. Am J Ophthalmol 136: 122-135, 2003
2. Aiello LP, Cahill MT, Wong JS: Systemic considerations in the management of diabetic retinopathy. Am J Ophthalmol 132:760-776, 2001
3. Ciulla TA, Amador AG, Zinman B: Diabetic retinopathy and diabetic macular edema: pathophysiology, screening, and novel therapies. Diabetes Care 26:2653-2664, 2003
4. Diabetes Control and Complications Trial Group: The effect of intensive diabetes treatment on the progression of diabetic retinopathy in insulin-dependent diabetes mellitus: the Diabetes Control and Complications Trial. Arch Ophthalmol 113:36-51, 1995
5. Chew EY, Klein ML, Ferris FL 3rd, Remaley NA, Murphy RP, Chantry K, Hoogwerf BJ, Miller D: Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy: Early Treatment Diabetic Retinopathy Study (ETDRS) report 22. Arch Ophthalmol 114:1079-1084, 1996
6. Ferris FL 3rd, Chew EY, Hoogwerf BJ: Serum lipids and diabetic retinopathy: Early Treatment. Diabetic Retinopathy Study Research Group. Diabetes Care 19:1291-1293, 1996
7. Roy MS, Klein R: Macular edema and retinal hard exudates in African Americans with type 1 diabetes: the New Jersey 725. Arch Ophthalmol 119:251-259, 2001
8. Klein BE, Moss SE, Klein R, Surawicz TS: The Wisconsin Epidemiologic Study of Diabetic Retinopathy. XIII. Relationship of serum cholesterol to retinopathy and hard exudate. Ophthalmology 98:1261-1265, 1991
9. Miyamoto K, Khosrof S, Bursell SE, Rohan R, Murata T, Clermont AC, Aiello LP, Ogura Y, Adamis AP: Prevention of leukostasis and vascular leakage in streptozotocin-induced diabetic retinopathy via intercellular adhesion molecule-1 inhibition. Proc Natl Acad Sci U S A 96:10836-10841, 1999
10. Joussen AM, Murata T, Tsujikawa A, Kirchhof B, Bursell SE, Adamis AP: Leukocyte-mediated endothelial cell injury and death in the diabetic retina. Am J Pathol 158:147-152, 2001
11. Joussen AM, Poulaki V, Mitsiades N, Kirchhof B, Koizumi K, Dohmen S, Adamis AP: Nonsteroidal anti-inflammatory drugs prevent early diabetic retinopathy via TNF-alpha suppression. FASEB J 16:438-440, 2002
12. DCCT Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus: the Diabetes Control and Complications Trial Research Group. N Engl J Med 329:977-986, 1993
13. Friedewald WT, Levy RI, Fredrickson DS: Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18:499-502, 1972
14. DCCT Research Group: The Diabetes Control and Complications Trial (DCCT): design and methodologic considerations for the feasibility phase: the DCCT Research Group. Diabetes 35:530-545, 1986
15. Early Treatment Diabetic Retinopathy Study Research Group: Fundus photographic risk factors for progression of diabetic retinopathy: ETDRS report number 12. Ophthalmology 98 (Suppl. 5):823-833, 1991
16. Early Treatment Diabetic Retinopathy Study Research Group: Grading diabetic retinopathy from stereoscopic color fundus photographs: an extension of the modified Airlie House classification: ETDRS report number 10. Ophthalmology 98:786-806, 1991
17. Kremser BG, Falk M, Kieselbach GF: Influence of serum lipid fractions on the course of diabetic macular edema after photocoagulation. Ophthalmologica 209:60-63, 1995
18. Larsson LI, Alm A, Lithner F, Dahlen G, Bergstrom R: The association of hyperlipidemia with retinopathy in diabetic patients aged 15-50 years in the county of Umea. Acta Ophthalmol Scand 77:585-591, 1999
19. el Haddad OA, Saad MK: Prevalence and risk factors for diabetic retinopathy among Omani diabetics. Br J Ophthalmol 82:901-906, 1998
20. Klein R, Klein BE, Moss SE, Cruickshanks KJ: The Wisconsin Epidemiologic Study of Diabetic Retinopathy. XV. The long-term incidence of macular edema. Ophthalmology 102:7-16, 1995
21. DCCT/EDIC Research Group: Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy: The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. N Engl J Med 342:381-389, 2000
22. Glasgow AM, August GP, Hung W: Relationships between control and serum lipids in juvenile-onset diabetes. Diabetes Care 4:76-80, 1981
23. Robins JM: Data, design, and background knowledge in etiologic inference. Epidemiology 12:313-320, 2001
24. Klein BE, Klein R, Moss SE: Is serum cholesterol associated with progression of diabetic retinopathy or macular edema in persons with younger-onset diabetes of long duration? Am J Ophthalmol 128:652-654, 1999
25. El-Asrar AM, Al-Rubeaan KA, Al-Amro SA, Kangave D, Moharram OA: Risk factors for diabetic retinopathy among Saudi diabetics. Int J Ophthalmol 22:155-161, 1998
26. The Lipid Research Clinics: Population Studies Data Book: The Prevalence Study. U.S. Department of Health and Human Services, National Institute of Health, 1980, p. 1-115 (NIH publ. no. 80-1527)
27. Chew EY, Ferris FL 3rd, Csaky KG, Murphy RP, Agron E, Thompson DJ, Reed GF, Schachat AP: The long-term effects of laser photocoagulation treatment in patients with diabetic retinopathy: the Early Treatment Diabetic Retinopathy Follow-up Study. Ophthalmology 110:1683-1689, 2003
28. ETDRS Study Group: Early Treatment Diabetic Retinopathy Study design and baseline patient characteristics: ETDRS report number 7. Ophthalmology 98:741-756, 1991
29. Sjolie AK, Stephenson J, Aldington S, Kohner E, Janka H, Stevens L, Fuller J: Retinopathy and vision loss in insulin-dependent diabetes in Europe: the EURODIAB IDDM Complications Study. Ophthalmology 104:252-260, 1997
30. Porta M, Sjoelie AK, Chaturvedi N, Stevens L, Rottiers R, Veglio M, Fuller JH: Risk factors for progression to proliferative diabetic retinopathy in the EURODIAB Prospective Complications Study. Diabetologia 44:2203-2209, 2001
31. Davis MD, Fisher MR, Gangnon RE, Barton F, Aiello LM, Chew EY, Ferris FL 3rd, Knatterud GL: Risk factors for high-risk proliferative diabetic retinopathy and severe visual loss: Early Treatment Diabetic Retinopathy Study report #18. Invest. Ophthalmol Vis Sci 39:233-252, 1998
32. The DCCT/EDIC Research Group: Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA 287:2563-2569, 2002
33. Cohen RA, Hennekens CH, Christen WG, Krolewski A, Nathan DM, Peterson MJ, LaMotte F, Manson JE: Determinants of retinopathy progression in type 1 diabetes mellitus. Am J Med 107:45-51, 1999
34. Ebeling P, Koivisto VA: Occurence and interrelationships of complications in insulin-dependent diabetes in Finland. Acta Diabetol 34:33-38, 1997
35. Kordonouri O, Danne T, Hopfenmuller W, Enders I, Hovener G, Weber B: Lipid profiles and blood pressure: are they risk factors for the development of early background retinopathy and incipient nephropathy in children with insulin-dependent diabetes mellitus? Acta Paediatr 85:43-48, 1996
36. Lyons TJ, Jenkins AJ, Zheng D, Lackland DT, McGee D, Garvey WT, Klein RL: Diabetic retinopathy and serum lipoprotein subclasses in the DCCT/ EDIC cohort. Invest Ophthalmol Vis Sci 45:910-918, 2004
37. Browning DJ, McOwen MD, Bowen RM Jr, O'Marah TL: Comparison of the clinical diagnosis of diabetic macular edema with diagnosis by optical coherence tomography. Ophthalmology 111:712-715, 2004
38. Landmesser U, Hornig B, Drexler H: Endothelial dysfunction in hypercholesterolemia: mechanisms, pathophysiological importance, and therapeutic interventions. Semin Thromb Hemost 26:529-537, 2000
39. c-(carboxymethyl)lysine ELISA. Diabetes Care 26:2609-2615, 2003
40. Frank RN: Diabetic retinopathy. N Engl J Med 350:48-58, 2004
41. Fong DS, Ferris FL 3rd, Davis MD, Chew EY: Causes of severe visual loss in the early treatment diabetic retinopathy study: ETDRS report no. 24: Early Treatment Diabetic Retinopathy Study Research Group. Am J Ophthalmol 127:137-141, 1999
42. White NH, Cleary PA, Dahms W, Goldstein D, Malone J, Tamborlane WV: Beneficial effects of intensive therapy of diabetes during adolescence: outcomes after the conclusion of the Diabetes Control and Complicatious Trial (DCCT). J Pediatr 139:804-812, 2001